Platinum Investment Management Ltd. lowered its holdings in shares of Infinity Pharmaceuticals Inc. (NASDAQ:INFI) by 8.9% during the 4th quarter, according to the company in its most recent filing with the SEC. The fund owned 1,286,032 shares of the biotechnology company’s stock after selling 125,800 shares during the period. Platinum Investment Management Ltd. owned about 2.54% of Infinity Pharmaceuticals worth $2,610,000 as of its most recent filing with the SEC.
Several other hedge funds have also added to or reduced their stakes in INFI. Ameriprise Financial Inc. bought a new position in shares of Infinity Pharmaceuticals during the 2nd quarter valued at $130,000. Dimensional Fund Advisors LP grew its holdings in shares of Infinity Pharmaceuticals by 32.7% during the 2nd quarter. Dimensional Fund Advisors LP now owns 652,481 shares of the biotechnology company’s stock valued at $1,024,000 after purchasing an additional 160,814 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in shares of Infinity Pharmaceuticals by 75.0% during the 2nd quarter. Goldman Sachs Group Inc. now owns 246,234 shares of the biotechnology company’s stock valued at $387,000 after purchasing an additional 105,497 shares during the last quarter. JPMorgan Chase & Co. bought a new position in shares of Infinity Pharmaceuticals during the 3rd quarter valued at $135,000. Finally, Clear Harbor Asset Management LLC bought a new position in shares of Infinity Pharmaceuticals during the 4th quarter valued at $312,000. 49.47% of the stock is currently owned by institutional investors.
INFI stock opened at $1.87 on Friday. Infinity Pharmaceuticals Inc. has a 52 week low of $0.93 and a 52 week high of $3.75. The firm has a market cap of $104.44, a P/E ratio of -2.25 and a beta of 2.49.
Infinity Pharmaceuticals (NASDAQ:INFI) last released its earnings results on Thursday, March 15th. The biotechnology company reported ($0.14) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.25) by $0.11. research analysts forecast that Infinity Pharmaceuticals Inc. will post -0.74 earnings per share for the current year.
COPYRIGHT VIOLATION WARNING: “Infinity Pharmaceuticals Inc. (NASDAQ:INFI) Holdings Cut by Platinum Investment Management Ltd.” was posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this piece on another publication, it was copied illegally and republished in violation of United States and international copyright & trademark legislation. The legal version of this piece can be viewed at https://www.dispatchtribunal.com/2018/04/07/infinity-pharmaceuticals-inc-infi-position-trimmed-by-platinum-investment-management-ltd.html.
About Infinity Pharmaceuticals
Infinity Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and delivery of medicines to treat diseases. The Company develops small molecule drugs that target disease pathways for potential applications in oncology. Its product candidate is duvelisib, also known as IPI-145, is an oral, dual-inhibitor of the delta and gamma isoforms of phosphoinositide-3-kinase (PI3K), for the treatment of hematologic malignancies, or blood cancers.
Receive News & Ratings for Infinity Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Infinity Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.